<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240513061779N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-12-20</date_registration>
      <primary_sponsor>Shomal university</primary_sponsor>
      <public_title>Comparison the effects of combined training with different rest intervals on anabolic and catabolic status, strength, and aerobic and anaerobic performance of volleyball players</public_title>
      <acronym></acronym>
      <scientific_title>Comparison the effect of 6 weeks of combined training with different rest intervals on serum levels of some anabolic and catabolic markers, aerobic and anaerobic performance, and strength in volleyball players</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-12-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/87009</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Block randomization with block size = 4 will be divided between the groups; the randomization list will be generated using the "Random allocation" software.
So that first, the subjects will be grouped in consecutive blocks of fixed size of 4 in the order of their entry into the study. For each block, a random sequence of group assignments will be generated by specialized "Random allocation" software. This software ensures that the order of the groups within each block is completely random. Then, each new volunteer is assigned to one of the study groups based on their, Blinding description: In order to prevent the Hawthorne and Avis effect, in the present study, the examiner (clinical caregiver) and the laboratory expert (responsible for evaluating blood samples) will not be aware of the content and titles of the groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Hormonal profile and performance of volleyball players.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Implementation of 6 weeks of simultaneous concurrent (resistance training with 75% to 95% of 1 repetition maximum + Aerobic training with 60% to 80% maximum oxygen uptake) training + Volleyball training. Intervention 2: Intervention group: Implementation of 6 weeks of concurrent (resistance training with 75% to 95% of 1 repetition maximum + Aerobic training with 60% to 80% maximum oxygen uptake) training with a 3-hour interval ratio + Volleyball training. Intervention 3: Intervention group: Implementation of 6 weeks of concurrent (resistance training with 75% to 95% of 1 repetition maximum + Aerobic training with 60% to 80% maximum oxygen uptake) training with a 24-hour interval ratio + Volleyball training. Intervention 4: Control group: Implementation of 6 weeks of volleyball training.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is No more information available.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammadreza Esmaelzadeh Toloee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Haraz street</address>
        <city>Amol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۶۱۶۱۸۴۵۹۶</zip>
        <telephone>+98 11 4420 3638</telephone>
        <email>r48.toloee@gmail.com</email>
        <affiliation>Shomal university</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nader Hamedchaman</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Haraz street</address>
        <city>Amol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۶۱۶۱۸۴۵۹۶</zip>
        <telephone>+98 11 4420 3638</telephone>
        <email>nader.hamedchaman@gmail.com</email>
        <affiliation>Shomal university</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>A documented history of 5 years of participation in the Premier League
No records of smoking
Absence of previous cardiovascular disease, and no history of blood, liver, kidney, or respiratory diseases.
Eligibility age at least 18 years old
No use of androgenic and ergogenic supplements for at least 3 months prior to the experiment</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>30 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Outfit the prerequisitive age range of 18 to 30 years old
Athletes with new functional injuries
Adding drug treatments that interfere with the hormonal profile or performance of athletes</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Implementation of 6 weeks of simultaneous concurrent (resistance training with 75% to 95% of 1 repetition maximum + Aerobic training with 60% to 80% maximum oxygen uptake) training + Volleyball training</i_keyword>
      <i_keyword>Intervention group: Implementation of 6 weeks of concurrent (resistance training with 75% to 95% of 1 repetition maximum + Aerobic training with 60% to 80% maximum oxygen uptake) training with a 3-hour interval ratio + Volleyball training</i_keyword>
      <i_keyword>Intervention group: Implementation of 6 weeks of concurrent (resistance training with 75% to 95% of 1 repetition maximum + Aerobic training with 60% to 80% maximum oxygen uptake) training with a 24-hour interval ratio + Volleyball training</i_keyword>
      <i_keyword>Control group: Implementation of 6 weeks of volleyball training</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Serum testosterone levels. Timepoint: Before and 48 hours subsequent to the 8 weeks of complex training. Method of measurement: ELISA technique.</prim_outcome>
      <prim_outcome>Serum cortisol levels. Timepoint: Before and 48 hours subsequent to the 8 weeks of complex training. Method of measurement: ELISA technique.</prim_outcome>
      <prim_outcome>Serum growth hormone levels. Timepoint: Before and 48 hours subsequent to the 8 weeks of complex training. Method of measurement: ELISA technique.</prim_outcome>
      <prim_outcome>Serum insulin-like growth factor levels. Timepoint: Before and 48 hours subsequent to the 8 weeks of complex training. Method of measurement: ELISA technique.</prim_outcome>
      <prim_outcome>Anaerobic power. Timepoint: Before and 48 hours subsequent to the 8 weeks of complex training. Method of measurement: Sargent jump test.</prim_outcome>
      <prim_outcome>Aerobic training. Timepoint: Before and 48 hours subsequent to the 8 weeks of complex training. Method of measurement: 1600 meter running test.</prim_outcome>
      <prim_outcome>Definite strength. Timepoint: Before and 48 hours subsequent to the 8 weeks of complex training. Method of measurement: Dynamometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shomal university</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-07-15</approval_date>
        <contact_name>Ethics Committee of Sport Sciences Research Institute</contact_name>
        <contact_address>No. 3, 5th Alley, Miremad Street, Motahhari Street Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
